Market Overview

ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018

Share:

ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Marc Schegerin, Senior Vice President, Strategy,
Communication and Finance, will present at the 20th Annual
Rodman & Renshaw Global Investment Conference, sponsored by H.C.
Wainwright & Co., LLC, on September 5, 2018, at 12:05pm ET at the St.
Regis New York Hotel in New York City.

The live webcast of the presentation will be available via the
"Investors & Media" section of ArQule's website, www.arqule.com,
under "Events & Presentations." A replay of the webcast will be
available shortly after the conclusion of the presentation.

About ArQule

ArQule is a biopharmaceutical company engaged in the research and
development of targeted therapeutics to treat cancers and rare diseases.
ArQule's mission is to discover, develop and commercialize novel small
molecule drugs in areas of high unmet need that will dramatically extend
and improve the lives of our patients. Our clinical-stage pipeline
consists of five drug candidates, all of which are in targeted,
biomarker-defined patient populations, making ArQule a leader among
companies our size in precision medicine. ArQule's pipeline includes:
ARQ 531, an orally bioavailable, potent and reversible inhibitor of both
wild type and C481S-mutant BTK, in Phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; Miransertib (ARQ
092), a selective inhibitor of the AKT serine/threonine kinase, in a
Phase 1/2 company-sponsored study for Overgrowth Diseases, in a Phase 1
study for ultra-rare Proteus syndrome conducted by the National
Institutes of Health (NIH), and in Phase 1b in combination with the
hormonal therapy, anastrozole, in patients with advanced endometrial
cancer; ARQ 751, a next generation AKT inhibitor, in Phase 1 for
patients with AKT1 and PI3K mutations; Derazantinib, a multi-kinase
inhibitor designed to preferentially inhibit the fibroblast growth
factor receptor (FGFR) family, in a registrational trial for iCCA; and
ARQ 761, a β-lapachone analog being evaluated as a promoter of
NQO1-mediated programmed cancer cell necrosis, in Phase 1/2 in multiple
oncology indications in partnership with the University of Texas
Southwestern Medical Center. ArQule's current discovery efforts are
focused on the identification and development of novel kinase
inhibitors, leveraging the Company's proprietary library of compounds.

View Comments and Join the Discussion!